Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement

Table of Contents

TLDR:

Inhibikase offers $100M to fund PAH treatment, stock dips 1.92%.
Inhibikase raises $100M via 46M shares for PAH drug development.
Stock dips as Inhibikase announces $100M offering for PAH therapy.
Inhibikase targets $100M raise to advance PAH drug, stock down 1.92%.
Inhibikase’s $100M offering aims to fund IKT-001 for pulmonary hypertension

Inhibikase Therapeutics, Inc. (IKT) saw its stock price drop by 1.92% to close at $1.5300 following the announcement of a $100 million public offering.

IKT Stock Card
Inhibikase Therapeutics, Inc., IKT

The company is set to offer over 46 million shares of common stock and pre-funded warrants, aimed at raising capital for its ongoing work in pulmonary arterial hypertension (PAH). Despite the downturn in stock price, the offering is expected to close on November 24, 2025, pending customary closing conditions.

Public Offering Details and Pricing

Inhibikase’s public offering consists of 46,091,739 shares of common stock and pre-funded warrants for 22,873,779 shares of common stock. The offering price for the common stock is set at $1.45 per share, while the pre-funded warrants are priced at $1.449, which reflects a slight premium over the common stock price. This capital raise will help fund the company’s development programs, including their lead product candidate, IKT-001, a treatment for PAH.

The underwriters have been granted a 30-day option to purchase an additional 10,344,827 shares at the offering price, further increasing the total proceeds. The gross proceeds from this offering are expected to be around $100 million, before deducting underwriting commissions and offering expenses. All securities are being sold by Inhibikase under a shelf registration statement filed with the Securities and Exchange Commission (SEC).

Role of Underwriters and Expected Impact

The offering is being managed by Jefferies, BofA Securities, and Cantor, with LifeSci Capital and Oppenheimer & Co. serving as co-lead managers. H.C. Wainwright & Co. and Ladenburg Thalmann & Co. are also involved as co-managers. The securities are being offered by Inhibikase under a previously filed shelf registration, and a final prospectus will be filed with the SEC in due course.

Although the stock price took a dip following the announcement, the company’s efforts to raise funds signal its commitment to advancing its pipeline of drugs targeting PAH. The proceeds will be used to support the clinical development of IKT-001, Inhibikase’s lead therapeutic candidate designed to treat PAH, a rare and progressive disease.